## PRACTICAL FEASIBILITY RANKING
### Tier 1 (Immediately Feasible - Repurposing Opportunity)
1. **S1P Pathway (Hypothesis 7)**: Fingolimod/siponimod already approved, safety known, could be tested in myelopathy populations within 2-3 years
2. **Complement System (Hypothesis 3)**: Avacopan approved for vasculitis, eculizumab proven safe, strong mechanistic rationale
### Tier 2 (Feasible with Significant Investment)
3. **JAK/STAT3 (Hypothesis 5)**: Need CNS-penetrant compounds, but pathway validated
4. **VEGF/Barrier (Hypothesis 2)**: Only if pursuing barrier-protective rather than inhibitory approach
### Tier 3 (High Risk/Poor Feasibility)
5. **Microglia (Hypothesis 1)**: Safety concerns, previous failures
6. **Ferroptosis (Hypothesis 6)**: Druggability challenges
7. **ER Stress (Hypothesis 4)**: Unacceptable safety profile
## INVESTMENT RECOMMENDATIONS
**Immediate Action (6-12 months):**
- **S1P Repurposing Study**: $2-5M investigator-initiated trial of fingolimod in acute myelitis
- **Complement Biomarker Study**: $1-3M to validate C5a levels across myelopathy etiologies
**Medium-term Investment (2-5 years):**
- **CNS-penetrant JAK inhibitors**: $50-100M medicinal chemistry program
- **Complement pathway expansion**: $20-50M to test avacopan in broader myelopathy indications
**Avoid:**
- Any PERK/ER stress modulators (safety)
- Broad microglial inhibition (mechanism concerns)
**Reality Check:** The most pragmatic approach is repurposing existing drugs (fingolimod, avacopan) for proof-of-concept studies before committing to novel drug development. The convergent pathway hypothesis remains unproven and needs validation before major investment.